Imatinib mesylate, a 3-class antitumor drug of Zhongqi pharmaceutical, a subsidiary of Shiyao group, has entered the site for on-site inspection

According to the website of CFDA on June 11, imatinib mesylate, a class 3.1 chemical applied for production by Zhongqi pharmaceutical, a subsidiary of Shiyao group, entered the site for inspection If there is no accident, the company is expected to obtain the product production approval document within the year At present, Jiangsu Haosen and Zhengda Tianqing are the only producers of this kind of APIs and preparations in China Imatinib mesylate is the first targeted anti-tumor drug developed by Novartis in Switzerland It is internationally recognized as the first-line treatment drug for chronic myeloid leukemia Because of the high price of imported drugs, only a few patients in China can use imatinib mesylate The patent protection period of the drug has expired in April 2013, and Jiangsu Haosen and Zhengda Tianqing have realized the first batch of domestic imitation in July last year In October last year, imatinib mesylate, which was first imitated by Zhengda Tianqing and Jiangsu Haosen, was included in the medical insurance catalogue of Fujian Province Imatinib generic drugs were included in the local medical insurance for the first time, promoting the sales of domestic drugs At present, more than 20 enterprises are applying for approval to produce imatinib mesylate APIs and preparations, including Jincheng pharmaceutical, Fuan pharmaceutical, Haizheng pharmaceutical, Qilu pharmaceutical, etc Shiyao group has said that it will further deepen generic drugs and first-class drugs with high added value, such as tumor drugs, on the basis of its strategy this year, especially in terms of anti-tumor drugs.